For decades, nanotechnology promised a revolution in cancer therapy: engineer a microscopic vehicle, load it with potent chemotherapeutics, and let it navigate the bloodstream to destroy tumors while sparing healthy tissue. However, the clinical translation of these nanocarriers has hit a stubborn roadblock.
As highlighted by Xixi Wu et al. in their review on biopolymer-based nanomedicine, the field faces a severe efficiency bottleneck: typically, less than one percent of an administered nanoparticle dose successfully reaches a solid tumor (Wu et al.). This phenomenon, often called the "0.7% problem," is corroborated by Jiale Zou et al., who note that median delivery efficiencies consistently fall below this threshold (Zou et al.). Even in highly aggressive malignancies like glioblastoma, systemic administration yields minimal localized accumulation (Yu et al.).
To fix this bottleneck, we must understand why it happens. The human body is not a passive pipeline; it is an active, multi-layered defense system. For a nanoparticle to work, it must survive a sequential biological gauntlet.
The Biological Gauntlet
When a nanoparticle enters the bloodstream, it immediately encounters three sequential barriers: clearance, transport, and penetration.
[ Injection ] ──> ( Protein Corona / MPS Clearance ) ──> ( Interstitial Fluid Pressure ) ──> ( Dense Extracellular Matrix ) ──> [ Tumor Cell ]
1. The Bloodstream: Opsonization and Immune Clearance
The moment a synthetic nanoparticle enters the blood, plasma proteins spontaneously adsorb onto its surface, forming a layer known as a protein corona. As explained by Wei Li et al., this corona fundamentally alters the nanoparticle’s biological identity (Li et al.). Instead of appearing as an inert drug carrier, the particle is flagged as a foreign invader.
Cells of the mononuclear phagocyte system (MPS)—primarily macrophages in the liver and spleen—recognize these proteins and rapidly engulf and clear the nanoparticles from circulation (Wu et al.). If a particle is cleared within minutes, it never stands a chance of reaching the tumor.
2. The Tumor Border: The Failure of Passive Transport
Historically, nanomedicine relied on the Enhanced Permeability and Retention (EPR) effect. The narrative was simple: tumors grow so fast that their blood vessels are leaky and defective, allowing nanoparticles to passively slip out of the bloodstream and accumulate in the tumor tissue.
However, Bin Zhang et al. point out that relying solely on passive accumulation is insufficient for deep tumor penetration (Zhang et al.). Because tumor vessels are leaky, fluid continuously escapes into the tumor interstitium. Without a functional lymphatic system to drain this fluid, the interstitial fluid pressure (IFP) inside the tumor skyrockets. This creates an outward pressure gradient that actively pushes arriving nanoparticles away, neutralizing passive diffusion.
3. The Tumor Core: The Dense Extracellular Matrix
If a nanoparticle manages to cross the vessel wall against the pressure gradient, it hits a physical wall: the dense tumor stroma and extracellular matrix (Chen et al.). Solid tumors are packed with cross-linked collagen and high cellular density, creating a tortuous path that restricts the movement of large particles. Consequently, drugs fail to reach the tumor core, leaving pockets of cancer cells untouched and free to mutate or metastasize (Wang et al.; Mo et al.).
Strategy 1: Biomimetic Cloaking to Evade the Immune System
To extend circulation time and prevent immediate clearance by the MPS, researchers have turned to biomimicry: wrapping synthetic nanoparticles in natural cell membranes.
As reviewed by Shu Zhang et al., cell membrane-coated nanoparticles (CMC@NPs) inherit the complex surface chemistry of the source cell (Zhang et al.). For example, coating a polymer core with a red blood cell membrane transfers self-recognition proteins (like CD47) to the nanoparticle. When an immune cell encounters this cloaked particle, the CD47 protein sends a "don't eat me" signal, tricking the MPS into ignoring it.
Synthetic Core + Cell Membrane Cloak ──> Biomimetic Nanoparticle
[ Toxic Payload ] [ "Don't Eat Me" Signals ] [ Long Circulation / Low Clearance ]
Similarly, researchers are leveraging exosomes—naturally occurring nano-vesicles secreted by cells. Jiantao Mo et al. demonstrated that encapsulating synthetic mPEG-PLGA nanoparticles inside exosomes significantly improves tumor accumulation and infiltration (Mo et al.). Because exosomes are native to the biological environment, they bypass the protein-corona-driven clearance mechanisms that plague entirely synthetic systems (Zhou et al.).
Strategy 2: Active Transport and Physical Optimization
Evading the immune system keeps nanoparticles in the blood longer, but it does not solve the problem of penetrating the dense tumor stroma. To overcome physical barriers, the architecture and targeting mechanisms of the nanocarriers must be finely tuned.
Size and Molecular Weight Optimization
The physical dimensions of a nanocarrier dictate its behavior in tissue. If a particle is too large, it cannot navigate the dense extracellular matrix; if it is too small, it is rapidly filtered out by the kidneys.
Yi Ma et al. systematically investigated this balance by optimizing the molecular weight of octyl chitosan nanocarriers (Ma et al.). They discovered that a 10 kDa formulation achieved the ideal equilibrium: it was small enough to penetrate deep into the dense tumor tissue but large enough to maintain structural stability and avoid premature drug release, resulting in superior therapeutic outcomes.
Active Biochemical Guidance
To move beyond passive accumulation, modern nanocarriers use active targeting ligands that bind to receptors overexpressed on tumor cells or vasculature. For instance, Haijun Wang et al. utilized Her2-specific affibodies to guide cisplatin-loaded nanoparticles directly to ovarian tumor masses, ensuring uptake by cells that might otherwise evade treatment (Wang et al.).
Passive Diffusion (EPR) ──> Stalls at tumor border due to high fluid pressure
Active Peptide Guidance ──> Triggers receptor-mediated transcytosis through tissue layers
Taking this further, Chen Chen et al. engineered a living medicine system using Lactococcus lactis bacteria camouflaged with red blood cell membranes and functionalized with iRGD, a tumor-penetrating peptide (Chen et al.). The iRGD peptide binds to integrins on the tumor endothelium and activates an endocytic/exocytic transport pathway. This actively pulls the therapeutic payload through successive layers of tissue, overcoming the high interstitial pressure that halts standard nanoparticles.
Cellular Hitchhiking
Another approach to overcoming physical barriers like the blood-brain barrier (BBB) is to hitchhike inside living cells that naturally possess homing capabilities. Ying Zhu et al. loaded doxorubicin nanoparticles into primary M1 macrophages (Zhu et al.). Macrophages naturally migrate toward inflammatory gradients and tumor sites, crossing endothelial barriers that block synthetic particles. By using the cell as a living transport vehicle, the authors successfully delivered therapeutics across the BBB for efficient glioma therapy.
Visualizing the Path Forward
To validate these complex transport strategies, researchers require precise tools to observe nanoparticles in vivo. As reviewed by Meng Li et al., Near-Infrared II (NIR-II) fluorescence imaging allows real-time tracking of nanomedicines deep within tissues (Li et al.). This feedback loop enables investigators to see exactly where a particle stalls—whether it is cleared by the liver or blocked by the tumor stroma—and iteratively refine the carrier's design.
The transition from purely synthetic, passive nanoparticles to active, biomimetic, and physically optimized systems represents a paradigm shift. By systematically addressing immune clearance with cellular cloaking and overcoming stromal resistance with active transport mechanisms, modern nanomedicine aims to finally break through the one percent delivery bottleneck.
Key Foundational Work
Optimizing molecular weight of octyl chitosan as drug carrier for improving tumor therapeutic efficacy (2017) — contributed 1 concept elements to this direction.
Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of Paclitaxel (2011) — contributed 1 concept elements to this direction.